Related Experiment Video

Updated: May 10, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

ABCG2: recent discovery of potent and highly selective inhibitors

Florine Lecerf-Schmidt1, Basile Peres, Glaucio Valdameri

  • 1Université Joseph Fourier, Grenoble 1, CNRS UMR 5063, Département de Pharmacochimie Moléculaire, Grenoble, France.

Future Medicinal Chemistry
|June 6, 2013
PubMed

Insights

ATP-binding cassette sub-family G member 2 (ABCG2) influences drug distribution and can cause cancer chemoresistance. New ABCG2 inhibitors are crucial for improving drug bioavailability and cancer therapy.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • The ABCG2 transporter significantly affects the absorption, distribution, and excretion of various drugs, including anticancer and anti-infectious agents.
  • High expression of ABCG2 at physiological barriers controls drug distribution, and its elevated levels in cancers contribute to multidrug resistance.
  • ABCG2 is a clinically relevant target for overcoming multidrug resistance and improving drug delivery.

Purpose of the Study:

  • To review and discuss novel ABCG2 inhibitors discovered in the last five years.
  • To highlight the therapeutic potential of ABCG2 inhibitors in cancer treatment and drug bioavailability enhancement.
  • To emphasize the need for selective, potent, and safe ABCG2 inhibitors.

Main Methods:

  • Literature review of recent studies on ABCG2 inhibitors.
  • Analysis of inhibitor selectivity, potency, and safety profiles.
  • Discussion of clinical relevance and therapeutic applications.

Main Results:

  • Recent research has focused on developing novel ABCG2 inhibitors with improved properties.
  • These inhibitors show promise in blocking drug efflux from cancer cells and enhancing oral bioavailability.
  • The development of selective and potent ABCG2 inhibitors is critical for clinical success.

Conclusions:

  • ABCG2 inhibitors represent a promising therapeutic strategy for both enhancing drug bioavailability and overcoming cancer multidrug resistance.
  • Further investigation and development of new ABCG2 inhibitors with favorable safety and efficacy profiles are warranted.
  • The dual application of ABCG2 inhibitors in oncology and pharmacokinetics underscores their therapeutic significance.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...